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New treatments for atopic dermatitis
Good news, but when and how to use tacrolimus and pimecrolimus is a muddle
Atopic dermatitis now affects 15% to 20% of chil›dren in developed countries, and prevalencein cities in developing countries undergoing
rapid demographic changes is quickly following suit.1
Most cases of atopic dermatitis in a given community
are mild, but children with moderate to severe disease
can have continuous itching and associated loss of
sleep. The social stigma of a visible skin disease can also
be soul destroying for both patient and family. A few
studies have suggested that some degree of prevention
of the disease is possible,2 although these measures
have not been taken up widely. In the absence of any
treatment that is known to alter the clinical course of
the disease, most treatment is aimed at reducing symp›
toms and signs. After a relative lull of almost 40 years,
new drugs—tacrolimus and pimecrolimus—have
appeared that offer different approaches to managing
this miserable disease. Do they work? Are they safe?
And how do they compare with existing treatments?
A suitable place to start putting the 47 existing
treatments into context is the NHS health technology
assessment systematic review of randomised controlled
trials for atopic dermatitis.3 This report concluded that
the evidence base for the treatment of atopic dermati›
tis is characterised by poor standards of reporting of
clinical trials and a lack of common outcome measures
that are important to patients. The direction of trials
over the past 40 years has been driven largely by the
agenda of the pharmaceutical industry with a
profusion of short term trials of “me too” products and
a lack of comparative data that help clinicians answer
the question “which is the best?” Good randomised
controlled trials support some treatments, such as
ultraviolet light, but provide no evidence for some
commonly used rituals such as combinations of topical
antibiotic and corticosteroid or antiseptic bath
additives. Enough evidence to make clear recommen›
dations on interventions like Chinese herbal treatment
is lacking, and there is no evidence from randomised
controlled trials on issues such as organisation of care
or use of water softeners. So, do the new treatments
help us to move forward?
Tacrolimus and pimecrolimus are two new topical
preparations that have been or are in the process of
being licensed throughout the world for use in atopic
dermatitis. They are similar macrolactam molecules
that probably work by suppressing T lymphocyte
responses through inhibiting calcineurin.4 Unlike topi›
cal steroids, they do not cause skin thinning, which
could be a major advantage for long term use.5
Do they work? In comparison with placebo, the
answer is an unreserved yes. However, clinicians are
often more interested in how new treatments compare
with existing treatments such as topical corticosteroids,
and this is where the evidence is unclear. Tacrolimus
seems to be equivalent to potent topical steroids,6–8 and
it is clearly superior to weak preparations such as 1%
hydrocortisone.9 Pimecrolimus, on the other hand, has
not been compared with 1% hydrocortisone, and when
compared with betamethasone, a commonly used
potent topical steroid, it seems to be nowhere near as
effective.10 Interestingly, topical tacrolimus and pime›
crolimus seem not to have been compared, but it takes
little imagination to predict which would emerge as the
most effective.
If topical tacrolimus is indeed equivalent to a potent
topical steroid, how should it be used – as monotherapy,
instead of topical steroids, or only when topical steroids
fail? The current wording of product licences suggests
that it should be used for people with moderate to severe
disease “who have failed to respond adequately to
conventional therapy”—that is, as a second line agent.
None of the randomised controlled trials, however, have
included such people. True tropical steroid failures—that
is, those patients who “get stuck” needing continuous
use or those who develop local side effects such as thin›
ning of the skin—are rare nowadays. Nevertheless, it
seems reasonable to use topical tacrolimus in such
people, especially in more sensitive sites such as the face
or eyelids where local side effects of topical steroids
might be more of a problem.
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The place of pimecrolimus is even more unclear,
although given its probably lower potency, it is clearly
positioning itself to take on the weaker topical steroids in
people with mild to moderate atopic dermatitis. To
secure such a market, a recent study (published in
abstract form) found that early use of pimecrolimus pre›
vented more flares—which then needed treatment with a
potent topical steroid—when compared with the vehicle
(10th congress of European Academy of Dermato›
Venereology, Munich, 2001). This study documented a
steroid sparing effect and examined long term control,
which is appropriate in a chronic condition like atopic
dermatitis. But it was a placebo controlled study, and
early use of another active compound such as weak 1%
hydrocortisone may have also prevented such flares.
Both products have not been tested against current
optimal use of topical steroids in a pragmatic way—that
is, short bursts of once daily products for flare ups of
disease followed by periods of rest when only
emollients were used. Data on cost effectiveness are
also missing—an important consideration given that
topical tacrolimus is at least 10 times as expensive as
standard topical steroids.
Are these drugs safe? Studies done so far suggest
that they are—at least in the short term. It is, however,
worth remembering that these products are immuno›
suppressive drugs. Oral tacrolimus is one of the most
powerful immunosuppressive drugs known—hence its
use to prevent rejection of transplants.
Although systemic absorption seems to be low in
most people using these preparations, there is a need
for careful and long term surveillance for visceral and
skin cancers. This concern was recently reinforced
when the US Food and Drug Administration granted
the product licence for pimecrolimus on the basis of
preclinical studies showing increased photocarcino›
genicity and an increase in lymphomas and thyroid
adenomas in mice.11
It is tempting to discuss only pharmacological
developments and ignore other developments in the
management of atopic dermatitis, such as biological
approaches. Probiotics (harmless cultures of bacteria)
prevented atopic dermatitis in half the individuals who
participated in one study.12 Another study showed that
vaccination with Mycobacterium vaccae can have
substantial effects in ameliorating existing disease.13
Further trials are going on using these approaches, and
both approaches may make big contributions in the
prevention and management of atopic dermatitis.
Both topical tacrolimus and pimecrolimus are wel›
come additions to the treatment of atopic dermatitis.
Little doubt exists that they work and that they are
probably safe, at least in the short term. Yet, because of
the lack of essential comparisons, clinicians are left
confused as to how and when to use these drugs and
whether they are cost effective. Given the widespread
and often irrational fear of topical corticosteroids,
manufacturers of both drugs are likely to make a
handsome profit in return for their investment—an
inevitable consequence of the current licensing
processes and the complete lack of independent stud›
ies using appropriate comparators.
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Long term care for older people
Increasing pressure for change
Long term care is a reality for thousands of frailolder people, a source of great anxiety for manymore and, across the developed world, a politi›
cal hot potato that shows no sign of cooling. The heat
is fuelled by two factors. Firstly, current government
policy in many countries is widely perceived to be
unjust, with older people themselves paying an ever
greater proportion of the costs of health care.
Secondly, the rising percentage of older people in the
population, while fuelling doom laden economic
projections, is inexorably increasing the power of the
older vote, producing democratic pressure for change
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